Assessment of Susceptibility to Measles and Rubella

Preblud, Stephen R.

doi:10.1001/jama.1982.03320330030021

Cited by 40 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19] Data regarding those not on HAART to our knowledge are not published. Of note, while vaccine seroresponse rates in HIV-negative adults are approximately 95% for measles,[24] and 79–95% for mumps,[4] the studies highlighted above for HIV-infected adults report suboptimal seroresponse to measles vaccination varying substantially between 0 and 80%. Studies regarding mumps and rubella vaccination seroresponse rates in those with HIV are yet more scarce and primarily limited to children.…”

Section: Introductionmentioning

confidence: 99%

Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

Stermole

Grandits

Roediger

et al. 2011

Vaccine

View full text Add to dashboard Cite

We analyzed HIV viral load (VL) and CD4 count changes, and antibody responses following MMR vaccination of individuals in the U.S. Military HIV Natural History Study cohort. Cases receiving at least one dose of MMR vaccine after HIV diagnosis were matched 1:2 to HIV-positive controls not receiving the vaccine. Baseline was defined as time of vaccination for cases and indexed and matched to the time post-HIV diagnosis for controls. Changes in CD4 count and VL at 6, 12, 18 and 24 months were compared between cases and controls using a general linear model. Available sera from cases were tested for MMR seropositivity at baseline and post-vaccination at 6, 12, 18, and 24 months. Overall mean CD4 count change from baseline through 24 months was 20 (±23) cells/μL greater for cases than controls (p=0.39). Similar non-significant changes in CD4 cell count were seen in the subset of those not on HAART at baseline. VL changes were small and similar between groups (mean differential change −0.04 (±0.18) log10 copies/mL; p=0.84). Of 21 vaccinated participants with baseline serologic testing, 14 (67%) were reactive to measles, 19 (91%) to mumps, and 20 (95%) to rubella. Three (43%) of 7 participants nonreactive to measles developed measles IgG; for mumps, 1 (50%) of 2 developed mumps IgG; for rubella, 1 (100%) developed rubella IgG. MMR vaccination did not result in detrimental immunologic or virologic changes through 24 months post-vaccination.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

Stermole

Grandits

Roediger

et al. 2011

Vaccine

View full text Add to dashboard Cite

show abstract

“…shows that our search process revealed 687 unique studies in English, and shows the numbers of studies we excluded according to specific criteria. After review of papers, we further excluded 39 studies that focused on cost minimization for strategies related to: screening of health‐care workers, women of child‐bearing age (for rubella), military recruits, college students, children prior to revaccination, or students before school entry; communications and other measures to encourage vaccination; alternative delivery or vaccine presentations (including hypothetical options); treatment; and different screening tests . We also excluded 13 papers that reported costs only for outbreaks (including any outbreak response efforts that occurred) without analysis of a comparator .…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions

Thompson

Odahowski²

2014

Risk Analysis

View full text Add to dashboard Cite

Economic analyses for vaccine-preventable diseases provide important insights about the value of prevention. We reviewed the literature to identify all of the peer-reviewed, published economic analyses of interventions related to measles and rubella immunization options to assess the different types of analyses performed and characterize key insights. We searched PubMed, the Science Citation Index, and references from relevant articles for studies in English and found 67 analyses that reported primary data and quantitative estimates of benefit-cost or cost-effectiveness analyses for measles and/or rubella immunization interventions. We removed studies that we characterized as cost-minimization analyses from this sample because they generally provide insights that focused on more optimal strategies to achieve the same health outcome. The 67 analyses we included demonstrate the large economic benefits associated with preventing measles and rubella infections using vaccines and the benefit of combining measles and rubella antigens into a formulation that saves the costs associated with injecting the vaccines separately. Despite the importance of population immunity and dynamic viral transmission, most of the analyses used static models to estimate cases prevented and characterize benefits, although the use of dynamic models continues to increase. Many of the analyses focused on characterizing the most significant adverse outcomes (e.g., mortality for measles, congenital rubella syndrome for rubella) and/or only direct costs, and the most complete analyses present data from high-income countries.

show abstract

The contribution of field tests to measles surveillance and control: A review of available methods

Cutts

Brown²

1995

Reviews in Medical Virology

View full text Add to dashboard Cite

Assessment of Susceptibility to Measles and Rubella

Abstract: We conducted a serological and questionnaire study of

Cited by 40 publications

References 15 publications

Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions

The contribution of field tests to measles surveillance and control: A review of available methods

Contact Info

Product

Resources

About